| Literature DB >> 28258040 |
Lenka Varinska1, Peter Kubatka2, Jan Mojzis1, Anthony Zulli3, Katarina Gazdikova4, Pavol Zubor5, Dietrich Büsselberg6, Martin Caprnda7, Radka Opatrilova8, Iveta Gasparova9, Martin Klabusay10, Martin Pec11, Eitan Fibach12, Mariusz Adamek13, Peter Kruzliak14.
Abstract
The formation of new blood vessels plays a crucial for the development and progression of pathophysiological changes associated with a variety of disorders, including carcinogenesis. Angiogenesis inhibitors (anti-angiogenics) are an important part of treatment for some types of cancer. Some natural products isolated from marine invertebrates have revealed antiangiogenic activities, which are diverse in structure and mechanisms of action. Many preclinical studies have generated new models for further modification and optimization of anti-angiogenic substances, and new information for mechanistic studies and new anti-cancer drug candidates for clinical practice. Moreover, in the last decade it has become apparent that galectins are important regulators of tumor angiogenesis, as well as microRNA. MicroRNAs have been validated to modulate endothelial cell migration or endothelial tube organization. In the present review we summarize the current knowledge regarding the role of marine-derived natural products, galectins and microRNAs in tumor angiogenesis.Entities:
Keywords: Angiogenesis; Anti-angiogenics; Cancer therapy; Galectins; Marine natural products; microRNAs
Mesh:
Substances:
Year: 2017 PMID: 28258040 DOI: 10.1016/j.biopha.2017.02.071
Source DB: PubMed Journal: Biomed Pharmacother ISSN: 0753-3322 Impact factor: 6.529